Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology
Go back to Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 9.39 -0.16 (1.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.55 | 52 Week High | $82.81 | |||
| Open | $9.25 | 52 Week Low | $19.74 | |||
| Day High | $9.57 | P/E | N/A | |||
| Day Low | $8.85 | EPS | $-2.16 | |||
| Volume | 365,782 | |||||
